Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients

被引:12
作者
Chen, Changyong [1 ]
Qiu, Huaiming [2 ]
Yao, Yuanhui [3 ]
Zhang, Zishu [4 ]
Ma, Cong [4 ]
Ma, Yilong [5 ]
Zhao, Chang [5 ]
Xiang, Hua [3 ]
Zhao, Hui [6 ]
Zheng, Chuansheng [7 ]
Xiong, Bin [7 ]
Li, Haiping [1 ]
Long, Qingyun [8 ]
Zhou, Jun [8 ]
Luo, Chao [2 ]
Hu, Hongyao [6 ]
机构
[1] Cent South Univ, Dept Radiol, Xiangya Hosp, Changsha, Peoples R China
[2] Wuhan Gen Hospita Guangzhou Mil, Dept Radiol, 627 Wuluo Rd, Wuhan 430070, Peoples R China
[3] Hunan Prov Peoples Hosp, Dept Intervent, Changsha, Peoples R China
[4] Cent South Univ, Dept Radiol, Xiangya Hosp 2, Changsha, Peoples R China
[5] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Intervent Therapy, Nanning, Peoples R China
[6] Wuhan Univ, Renmin Hosp, Dept Radiol, Dept Intervent Radiol, Jiefang Rd 238, Wuhan 430060, Peoples R China
[7] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Intervent Radiol, Wuhan, Peoples R China
[8] Wuhan Univ, Zhongnan Hosp, Dept Radiol, Wuhan, Peoples R China
关键词
Prognostic factors; Drug-eluting bead-transarterial chemoembolization; Conventional transarterial chemoembolization; Treatment response; Survival; Hepatocellular carcinoma; CANCER STATISTICS; DEB-TACE; SAFETY; EFFICACY; TRIAL; CTACE;
D O I
10.1016/j.clinre.2020.05.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients who are not suitable for surgical treatment. We aimed to investigatethe treatment outcomes and comprehensive prognostic factors of CalliSpheres (R) microspheres(CSM) drug-eluting bead TACE (DEB-TACE) treatment and conventional TACE (cTACE) treatment in HCC patients. Methods: Three hundred and thirty-five HCC patients received DEB-TACE or cTACE treatment were consecutively enrolled in multi-center, retrospective cohort study. Treatment response was conducted at M1, M3 or M6 after treatment. Progression free survival (PFS) and overall survival (OS) were recorded. Thirty-seven baseline factors including demographic characteristics, clinical features, biochemical indexes and previous treatment histories were selected. Results: In total patients, history of drink and largest nodule size >= 7 cm independently predicted worse ORR, DEB-TACE predicted better OS, while largest nodule size >= 7 cm, increased Child-Pugh stage, ALB abnormal, ALP abnormal or AFP abnormal predicted worse survival. For DEB-TACE group, previous cTACE and ANC abnormal independently predicted worse ORR, and hepatic vein invasion, increased Child-Pugh stage or AFP abnormal independently predicted poor survival. For cTACE group, largest nodule size >= 7 cm independently predicted poor ORR, and multifocal disease as well as ALB abnormal predicted poor OS. Conclusions: History of drink, largest nodule size >= 7 cm, DEB-TACE, increased Child-Pugh stage, abnormal ALB, ALP or AFP are potential prognostic factors in total patients, previous cTACE and ANC abnormal, hepatic vein invasion, increased Child-Pugh stage or AFP abnormal are potential prognostic factors in DEB-TA group, and largest nodule size >= 7 cm, multifocal disease and ALB abnormal are potential prognostic factors in cTACE group. (c) 2020 Published by Elsevier Masson SAS.
引用
收藏
页数:11
相关论文
共 12 条
[1]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[2]   Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results [J].
Cosgrove, David P. ;
Reyes, Diane K. ;
Pawlik, Timothy M. ;
Feng, Allen L. ;
Kamel, Ihab R. ;
Geschwind, Jean-Francois H. .
RADIOLOGY, 2015, 277 (02) :594-603
[3]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Llovet, Josep M. ;
Bruix, Jordi .
LANCET, 2012, 379 (9822) :1245-1255
[4]   Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations [J].
Lencioni, Riccardo ;
de Baere, Thierry ;
Burrel, Marta ;
Caridi, James G. ;
Lammer, Johannes ;
Malagari, Katerina ;
Martin, Robert C. G. ;
O'Grady, Elizabeth ;
Isabel Real, Maria ;
Vogl, Thomas J. ;
Watkinson, Anthony ;
Geschwind, Jean-Francois H. .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2012, 35 (05) :980-985
[5]   Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial [J].
Llovet, JM ;
Real, MI ;
Montaña, X ;
Planas, R ;
Coll, S ;
Aponte, J ;
Ayuso, C ;
Sala, M ;
Muchart, J ;
Solà, R ;
Rodés, J ;
Bruix, J .
LANCET, 2002, 359 (9319) :1734-1739
[6]   Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [J].
Lo, CM ;
Ngan, H ;
Tso, WK ;
Liu, CL ;
Lam, CM ;
Poon, RTP ;
Fan, ST ;
Wong, J .
HEPATOLOGY, 2002, 35 (05) :1164-1171
[7]   Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma [J].
Ludwig, Johannes M. ;
Zhang, Di ;
Xing, Minzhi ;
Kim, Hyun S. .
EUROPEAN RADIOLOGY, 2017, 27 (05) :2031-2041
[8]   Global cancer statistics, 2002 [J].
Parkin, DM ;
Bray, F ;
Ferlay, J ;
Pisani, P .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) :74-108
[9]   Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study [J].
Xiang, Hua ;
Xiong, Bin ;
Li, Haiping ;
Zhao, Chang ;
Zhang, Zishu ;
Ma, Cong ;
Zheng, Chuansheng ;
Luo, Chao ;
Qiu, Huaiming ;
Yao, Yuanhui ;
Hu, Hongyao ;
Zhao, Hui ;
Long, Qingyun ;
Zhou, Jun ;
Chen, Changyong ;
Ma, Yilong .
TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) :1950-+
[10]   Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma [J].
Xie, Zhi-Bo ;
Wang, Xiao-Bo ;
Peng, Yu-Chong ;
Zhu, Shao-Liang ;
Ma, Liang ;
Xiang, Bang-De ;
Gong, Wen-Feng ;
Chen, Jie ;
You, Xue-Mei ;
Jiang, Jing-Hang ;
Li, Le-Qun ;
Zhong, Jian-Hong .
HEPATOLOGY RESEARCH, 2015, 45 (02) :190-200